- Company
- Camzyos’s reimbursement decision imminent
- by Moon, sung-ho Oct 4, 2024 04:38am
- Obstructive hypertrophic cardiomyopathy (oHCM), has been regarded as a difficult-to-treat area due to the lack of a cure. However, with the recent introduction of new drugs and reimbursement granted for its diagnostic test, expectations are rising for a paradigm shift in oHCM treatment &8211; the key to which will be whether or not the newly
- Company
- Expectations rise for the reimbursement of Phesgo in Korea
- by Whang, byung-woo Oct 4, 2024 04:38am
- On the 30th, Roche Korea announced that the socio-economic benefits of Phesgo (pertuzumab/trastuzumab) for early-stage and metastatic HER2-positive breast cancer were highlighted at the 2024 Korean Society of Medical Oncology (KSMO) Congress. The 2024 Korean Society of Medical Oncology (KSMO) Fall Meeting, which was held at COEX, brings t
- Company
- Biologics seek to expand indications…is approved for COPD
- by Son, Hyung Min Oct 4, 2024 04:38am
- Biological agents are expanding their reach beyond inflammatory diseases such as atopic dermatitis, oesophagitis, and asthma to lung disease. Recently, Sanofi and Regeneron's biologic Dupixent was approved by the US Food and Drug Administration (FDA) for the treatment of chronic obstructive pulmonary disease (COPD). Other biologics, such as GSK'
- Company
- "Importance of fungal infections TX amid COVID-19 spike"
- by Son, Hyung Min Oct 4, 2024 04:38am
- "Fungal infections usually occur in immunocompromised patients and have a high fatality rate. Because fungal infections can be fatal to patients, especially during the resurgence of infectious diseases, such as COVID-19, it is of paramount importance to secure various treatment options." During a recent meeting with Daily Pharm, Sung-Yeon
- Company
- Imfinzi builds evidence for biliary tract cancer reimb
- by Whang, byung-woo Oct 2, 2024 05:49am
- AstraZeneca is reattempting to extend reimbursement of its immuno-oncology drug imfinzi (durvalumab) after announcing significant clinical outcomes in biliary tract cancer. Amid the rising interest in Imfinzi’s reimbursement reapplication review, with patient petitions being posted on the National Assembly's e-petition website, the outcome
- Company
- Will the Imfinzi·Imjudo combo be reimb within the year?
- by Eo, Yun-Ho Oct 2, 2024 05:49am
- Whether the combination of the immuno-oncology drugs Imfinzi and Imjudo will be reimbursed for liver cancer in Korea is gaining attention. In June, AstraZeneca Korea submitted an application for the reimbursement of the PD-L1 inhibitor Imfinzi (durvalumab) and CTLA-4 inhibitor Imjudo (tremelimumab) combination for liver cancer. There
- Company
- "Expanded scope for the newborn screening test"
- by Whang, byung-woo Oct 2, 2024 05:48am
- "Conducting genetic testing on family members and related families when a baby is found to be a carrier from a newborn screening test can identify more individuals with carriers. For rare diseases, such as Gaucher's disease, early diagnosis improves the patient's quality of life and saves the societal cost." Starting this year, the items for
- Company
- Jardiance generics prepare for final launch in Korea
- by Kim, Jin-Gu Sep 30, 2024 05:47am
- Generic companies are in the midst of last-minute preparations to enter the market for the SGLT inhibitor diabetes drug Jardiance (empagliflozin), which is set to expire in just about half a year. With Forxiga’s market withdrawal expected to leave an annual sales gap of KRW 50 billion, the race to fill this gap is expected to intensify among
- Company
- New myelodysplastic syndrome drug 'Reblozyl' lands Big 5 DC
- by Eo, Yun-Ho Sep 30, 2024 05:46am
- The treatment for myelodysplastic syndrome (MDS), 'Reblozyl,' is available for prescription at tertiary general hospitals. Sources said that Bristol Myers Squibb (BMS) Pharmaceutical Korea's Reblozyl (luspatercept) has passed all drug committees (DC) of the 'Big 5' medical centers, including Samsung Medical Center, Seoul National Univers
- Company
- Phesgo can be prescribed in Korea with reimbursement
- by Eo, Yun-Ho Sep 30, 2024 05:46am
- Breast cancer biobetter ‘Phesgo’ can now be prescribed in general hospitals in Korea with insurance reimbursement. According to industry sources, Phesgo (pertuzumab/trastuzumab), which is a subcutaneous injection combination of Roche's Perjeta and Herceptin, has passed drug committees (DC) reviews of tertiary hospitals in Korea, includi
